Vidal-Calvo, Elena Ethel https://orcid.org/0000-0001-9655-2106
Martin-Salazar, Anne https://orcid.org/0009-0003-3831-8225
Choudhary, Swati
Dagil, Robert https://orcid.org/0000-0002-5594-0716
Raghavan, Sai Sundar Rajan https://orcid.org/0000-0002-2575-2685
Duvnjak, Lara
Nordmaj, Mie Anemone
Clausen, Thomas Mandel
Skafte, Ann https://orcid.org/0009-0006-1024-2224
Oberkofler, Jan
Wang, Kaituo https://orcid.org/0000-0002-5922-7109
Agerbæk, Mette Ø https://orcid.org/0000-0001-5865-2034
Løppke, Caroline https://orcid.org/0000-0003-0679-5118
Jørgensen, Amalie Mundt https://orcid.org/0000-0002-8554-7261
Ropac, Daria
Mujollari, Joana
Willis, Shona
Garcias López, Agnès
Miller, Rebecca Louise https://orcid.org/0000-0001-8574-1948
Karlsson, Richard Torbjörn Gustav https://orcid.org/0000-0003-0448-6135
Goerdeler, Felix https://orcid.org/0000-0002-7190-9145
Chen, Yen-Hsi https://orcid.org/0000-0001-9484-3145
Colaço, Ana R.
Wang, Yong https://orcid.org/0000-0001-9156-0377
Lavstsen, Thomas https://orcid.org/0000-0002-3044-4249
Martowicz, Agnieszka
Nelepcu, Irina https://orcid.org/0000-0002-9208-6934
Marzban, Mona
Oo, Htoo Zarni https://orcid.org/0009-0009-8514-2713
Ørum-Madsen, Maj Sofie
Wang, Yuzhuo https://orcid.org/0000-0002-9749-8591
Nielsen, Morten A. https://orcid.org/0000-0003-2668-4992
Clausen, Henrik https://orcid.org/0000-0002-0915-5055
Wierer, Michael
Wolf, Dominik
Gögenur, Ismail
Theander, Thor G.
Al-Nakouzi, Nader https://orcid.org/0000-0002-4653-2884
Gustavsson, Tobias
Daugaard, Mads https://orcid.org/0000-0001-8383-055X
Salanti, Ali https://orcid.org/0000-0003-2207-5575
Funding for this research was provided by:
Innovationsfonden (9065-00216A)
Novo Nordisk Fonden (NNF22OC0073736, NNF19SA0059305, NNF19OC0058387)
Carlsbergfondet (CF20-0412)
Danmarks Grundforskningsfond (DNRF107, DNRF107)
European Molecular Biology Organization (ALTF 105-2063)
National Keu Research and Development Program of China Fundamental Research Funds for the Central Universities of China
Lundbeckfonden (R344-2020-934, R324-2019-1855)
Gouvernement du Canada | Canadian Institutes of Health Research (PJT-470421)
Article History
Received: 9 October 2023
Accepted: 16 August 2024
First Online: 30 August 2024
Competing interests
: A.S., M.D., M.Ø.A., T.M.C., M.A.N., and T.G.T. are shareholders of VAR2 Pharmaceuticals. The antibodies are subject to a patenting process owned by VAR2 Pharmaceuticals. H.C. is a shareholder of GlycoDisplay ApS, GlycoZym ApS, GlycoZym Inc, now GO Therapeutics Inc. The remaining authors declare no competing interests.